This health tech company has made some significant changes in order to keep up with its growth. Photo via Getty Images

With a new CEO and chief operating officer aboard, Houston-based DataJoint is thinking small in order to go big.

Looking ahead to 2022, DataJoint aims to enable hundreds of smaller projects rather than a handful of mega-projects, CEO Dimitri Yatsenko says. DataJoint develops data management software that empowers collaboration in the neuroscience and artificial intelligence sectors.

"Our strategy is to take the lessons that we have learned over the past four years working with major projects with multi-institutional consortia," Yatsenko says, "and translate them into a platform that thousands of labs can use efficiently to accelerate their research and make it more open and rigorous."

Ahead of that shift, the startup has undergone some significant changes, including two moves in the C-suite.

Yatsenko became CEO in February after stints as vice president of R&D and as president. He co-founded the company as Vathes LLC in 2016. Yatsenko succeeded co-founder Edgar Walker, who had been CEO since May 2020 and was vice president of engineering before that.

In tandem with Yatsenko's ascent to CEO, the company brought aboard Jason Kirkpatrick as COO. Kirkpatrick previously was chief financial officer of Houston-based Darcy Partners, an energy industry advisory firm; chief operating officer and chief financial officer of Houston-based Solid Systems CAD Services (SSCS), an IT services company; and senior vice president of finance and general manager of operations at Houston-based SmartVault Corp., a cloud-based document management company.

"Most of our team are scientists and engineers. Recruiting an experienced business leader was a timely step for us, and Jason's vast leadership experience in the software industry and recurring revenue models added a new dimension to our team," Yatsenko says.

Other recent changes include:

  • Converting from an LLC structure to a C corporation structure to enable founders, employees, and future investors to be granted shares of the company's stock.
  • Shortening the business' name to DataJoint from DataJoint Neuro and recently launching its rebranded website.
  • Moving the company's office from the Texas Medical Center Innovation Institute (TMCx) to the Galleria area. The new space will make room for more employees. Yatsenko says the 12-employee startup plans to increase its headcount to 15 to 20 by the end of this year.

Over the past five years, the company's customer base has expanded to include neuroscience institutions such as Princeton University's Princeton Neuroscience Institute and Columbia University's Zuckerman Institute for Brain Science, as well as University College London and the Norwegian University of Science and Technology. DataJoint's growth has been fueled in large part by grants from the U.S. Defense Advanced Research Projects Agency (DARPA) and the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative at the National Institutes of Health (NIH).

"The work we are tackling has our team truly excited about the future, particularly the capabilities being offered to the neuroscience community to understand how the brain forms perceptions and generates behavior," Yatsenko says.

A Houston-based software startup received a multimillion-dollar grant from the National Institutes of Health for its work within neurophysiology. Getty Images

Data science startup based in Houston focus on neuroscience software nabs $3.78M grant

brain game

Armed with a nearly $3.8 million federal grant, a Houston startup aims to boost neuroscience research around the world.

Vathes LLC, a developer of data management software that collaborates with neuroscience research labs in North America and Europe, recently received the $3.78 million grant from the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative at the National Institutes of Health (NIH). That initiative is part of the National Institute of Neurological Disorders and Stroke.

Vathes says the NIH funding will enable the startup to ramp up its DataJoint Pipelines for Neurophysiology project. The project aims to make open-source software for data science and engineering available to researchers who specialize in neurophysiology, a branch of neuroscience that looks at how the nervous system functions. The pipeline project holds the promise of benefiting research in areas like autism, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease).

The project's principal investigator is Dimitri Yatsenko, vice president of research and development at Vathes. Technologically speaking, neuroscientists are playing catch-up with their counterparts in fields like astrophysics, genomics, and bioinformatics, according to Yatsenko.

Neuroscience "is undergoing a fast transformation in terms of moving toward much more data-centric, data-intensive, computation-intensive, and collaborative projects," Yatsenko says. This means that neuroscientists are "now finding themselves having to quickly adapt to an environment," he adds, "where they have to share big data and computations with their collaborators in very dynamic settings and perform them in a very fluid way."

Yatsenko says the NIH-funded project will help smaller research groups tap into the technical expertise of larger research labs.

Vathes' DataJoint Neuro platform and services, which help create so-called DataJoint pipelines, enable neuroscientists to streamline, analyze, and visualize complex data. Among its customers are Princeton University's Neuroscience Institute and Columbia University's Zuckerman Institute. The federally funded project will empower smaller labs to capitalize on existing DataJoint pipelines as ready-to-go turnkey packages, Yatsenko says.

In essence, Vathes' technology acts as a translator. Big research labs collect data in databases that can vary by computer language and platform. Through the Vathes setup, that data can be incorporated by a lab of any size into algorithmic, machine learning, and artificial intelligence mechanisms, regardless of the computer language or platform.

Edgar Walker, CEO of Vathes, says this simplifies the construction and use of databases, giving scientists "more room to focus on the logic of their data pipeline rather than on the physical implementation of it."

Founded in 2016, Vathes is housed at the Texas Medical Center's Innovation Institute. It employs 10 people. The startup previously received a $100,000 grant from the U.S. Defense Advanced Research Projects Agency (DARPA).

Yatsenko says the project backed by the $3.78 million NIH grant will propel the startup's growth, as it "gives us a big window of opportunity" to provide tools and services that support the startup's open-source software.

"As the NIH and other funding agencies are shifting a lot of their focus to collaborative projects that are distributed among multiple institutions," Walker says, "we've established a reputation as the company that can facilitate such research, be efficient, and actually be cost-effective as well, and make the projects very smooth."

"We expect to continue to grow this business at the same exponential rate," he adds. "We'll keep our fingers crossed and see how things go."


CEO Edgar Walker (left) and Dimitri Yatsenko, vice president of research and development, lead Houston-based Vathes. Photos courtesy of Vathes

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston engineers develop breakthrough device to advance spinal cord treatment

future of health

A team of Rice University engineers has developed an implantable probe over a hundred times smaller than the width of a hair that aims to help develop better treatments for spinal cord disease and injury.

Detailed in a recent study published in Cell Reports, the probe or sensor, known as spinalNET, is used to explore how neurons in the spinal cord process sensation and control movement, according to a statement from Rice. The research was supported by the National Institutes of Health, Rice, the California-based Salk Institute for Biological Studies, and the philanthropic Mary K. Chapman Foundation based in Oklahoma.

The soft and flexible sensor was used to record neuronal activity in freely moving mice with high resolution for multiple days. Historically, tracking this level of activity has been difficult for researchers because the spinal cord and its neurons move so much during normal activity, according to the team.

“We developed a tiny sensor, spinalNET, that records the electrical activity of spinal neurons as the subject performs normal activity without any restraint,” Yu Wu, a research scientist at Rice and lead author of the study said in a statement. “Being able to extract such knowledge is a first but important step to develop cures for millions of people suffering from spinal cord diseases.”

The team says that before now the spinal cord has been considered a "black box." But the device has already helped the team uncover new findings about the body's rhythmic motor patterns, which drive walking, breathing and chewing.

Lan Luan (from left), Yu Wu, and Chong Xie are working on the breakthrough device. Photo by Jeff Fitlow/Rice University

"Some (spinal neurons) are strongly correlated with leg movement, but surprisingly, a lot of neurons have no obvious correlation with movement,” Wu said in the statement. “This indicates that the spinal circuit controlling rhythmic movement is more complicated than we thought.”

The team said they hope to explore these findings further and aim to use the technology for additional medical purposes.

“In addition to scientific insight, we believe that as the technology evolves, it has great potential as a medical device for people with spinal cord neurological disorders and injury,” Lan Luan, an associate professor of electrical and computer engineering at Rice and a corresponding author on the study, added in the statement.

Rice researchers have developed several implantable, minimally invasive devices to address health and mental health issues.

In the spring, the university announced that the United States Department of Defense had awarded a four-year, $7.8 million grant to the Texas Heart Institute and a Rice team led by co-investigator Yaxin Wang to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation.

That same month, the university shared news that Professor Jacob Robinson had published findings on minimally invasive bioelectronics for treating psychiatric conditions. The 9-millimeter device can deliver precise and programmable stimulation to the brain to help treat depression, obsessive-compulsive disorder and post-traumatic stress disorder.

Houston clean hydrogen startup to pilot tech with O&G co.

stay gold

Gold H2, a Houston-based producer of clean hydrogen, is teaming up with a major U.S.-based oil and gas company as the first step in launching a 12-month series of pilot projects.

The tentative agreement with the unnamed oil and gas company kicks off the availability of the startup’s Black 2 Gold microbial technology. The technology underpins the startup’s biotech process for converting crude oil into proprietary Gold Hydrogen.

The cleantech startup plans to sign up several oil and gas companies for the pilot program. Gold H2 says it’s been in discussions with companies in North America, Latin America, India, Eastern Europe and the Middle East.

The pilot program is aimed at demonstrating how Gold H2’s technology can transform old oil wells into hydrogen-generating assets. Gold H2, a spinout of Houston-based biotech company Cemvita, says the technology is capable of producing hydrogen that’s cheaper and cleaner than ever before.

“This business model will reshape the traditional oil and gas industry landscape by further accelerating the clean energy transition and creating new economic opportunities in areas that were previously dismissed as unviable,” Gold H2 says in a news release.

The start of the Black 2 Gold demonstrations follows the recent hiring of oil and gas industry veteran Prabhdeep Singh Sekhon as CEO.

“With the proliferation of AI, growth of data centers, and a national boom in industrial manufacturing underway, affordable … carbon-free energy is more paramount than ever,” says Rayyan Islam, co-founder and general partner at venture capital firm 8090 Industries, an investor in Gold H2. “We’re investing in Gold H2, as we know they’ll play a pivotal role in unleashing a new dawn for energy abundance in partnership with the oil industry.”

------

This article originally ran on EnergyCapital.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes an e-commerce startup founder, an industrial biologist, and a cellular scientist.

Omair Tariq, co-founder and CEO of Cart.com

Omair Tariq of Cart.com joins the Houston Innovators Podcast to share his confidence in Houston as the right place to scale his unicorn. Photo via Cart.com

Houston-based Cart.com, which operates a multichannel commerce platform, has secured $105 million in debt refinancing from investment manager BlackRock.

The debt refinancing follows a recent $25 million series C extension round, bringing Cart.com’s series C total to $85 million. The scaleup’s valuation now stands at $1.2 billion, making it one of the few $1 billion-plus “unicorns” in the Houston area.

Cart.com was co-founded by CEO Omair Tariq in October 2020. Read more.

Nádia Skorupa Parachin, vice president of industrial biotechnology at Cemvita

Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos. Read more.

Han Xiao, associate professor of chemistry at Rice University

The funds were awarded to Han Xiao, a chemist at Rice University.

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories. Xiao will use the five-year grant to advance his work on noncanonical amino acids.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement. Read more.